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Abstract
Engineered nanoparticles are finding a wide spectrum of biomedical applications, including drug delivery and capacity
to trigger cytotoxic phenomena, potentially useful against tumor cells. The full understanding of their biosafety and
interactions with cell processes is mandatory. Using microglial (BV-2) and alveolar basal epithelial (A549) cells, in this
study we determined the effects of engineered carbon nanodiamonds (ECNs) on cell viability, nitric oxide (NO) and
reactive oxygen species (ROS) production, as well as on energy metabolism. Particularly, we initially measured
decrease in cell viability as a function of increasing ECNs doses, finding similar cytotoxic ECN effects in the two cell
lines. Subsequently, using apparently non-cytotoxic ECN concentrations (2 µg/mL causing decrease in cell number <
5%) we determined NO and ROS production, and measured the concentrations of compounds related to energy
metabolism, mitochondrial functions, oxido-reductive reactions, and antioxidant defences. We found that in both cell
lines non-cytotoxic ECN concentrations increased NO and ROS production with sustained oxidative/nitrosative stress,
and caused energy metabolism imbalance (decrease in high energy phosphates and nicotinic coenzymes) and
mitochondrial malfunctioning (decrease in ATP/ADP ratio).
These results underline the importance to deeply investigate the molecular and biochemical changes occurring upon
the interaction of ECNs (and nanoparticles in general) with living cells, even at apparently non-toxic concentration.
Since the use of ECNs in biomedical field is attracting increasing attention the complete evaluation of their biosafety,
toxicity and/or possible side effects both in vitro and in vivo is mandatory before these highly promising tools might
find the correct application.
Introduction
Nanotechnology is considered one of the most pro-
mising field of applied research which is worldwide
receiving considerable attention even from the media.
Nanotechnology is producing impressive improvements
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in different disciplines on a large scale, such as physics
and engineering. Even in medicine, nanotechnology offers
great promises for new strategies of delivering that involve
the use of nano-sized particles (nanoparticles)1.
In the last decade, engineered nanoparticles have found a
wide spectrum of applications that range from energy
production2 to industrial production processes3 to biome-
dical applications4, 5. The latter includes drugs delivery to
tumors6–8, break up clusters of bacteria enhancing bacterial
killing9, stimulation of immune responses10, 11, improve-
ment of non-invasive imaging methods12, and scavenging
of reactive oxygen species (ROS)13. Even though engi-
neered nanoparticles use is becoming indispensable in
many areas of human activity the debate regarding their
toxicity and other side effects is still open14, 15.
Among the various types of engineered nanoparticles
currently under investigation, we focused our attention on
the effect of carbon nanoparticles, specifically engineered
carbon nanodiamonds (ECNs), on brain and lung cells. It
has already been shown that ECNs are able to induce
alterations in lipid mixture mimicking the cell plasma
membranes as a function of phospholipid headgroup
charge and alkyl chain saturation in vitro16. Many factors,
including size and shape, can influence the activity and
toxicity of carbon nanoparticles17. Since they are fre-
quently employed in a broad array of industrial and sci-
entific commercial products and might become more
easily inhalable at different stages of their life cycle18, the
probability for human being to get in close contact with
them is considerably increasing19, 20.
It has been widely shown that nanoparticles and their
agglomerates in the range size of 10−200 nm, after
inspiration, are significantly accumulated in the alveolar
regions of the lungs, interacting with a complex mixture
of essential molecules, such as lipids, proteins, and car-
bohydrates, forming the so called lung surfactants (LS)21.
Two of the most important functions of LS are to form
the first line of defence against any foreign particles22 and
to maintain a low surface tension in the lung thus pre-
venting their collapse23, 24. However, since it is highly
probable that inhaled ECNs are not confined in the
respiratory tract, it is important to investigate the effect
and toxicity of ECNs on cell systems representative of
additional relevant human tissues other than lungs. To
this purpose, it is also worth recalling that ECNs have also
recently been studied as a novel potential drug delivery
system for treatment of malignant brain gliomas25, as well
as in neurodegenerative disorders such as Alzheimer's
disease26.
In the present study, the influence of different con-
centrations of ECNs in absence or presence of LS (DPPC:
POPG(7:3)) on A549 and BV-2 cell toxicity was firstly
investigated. Human alveolar basal epithelial cells A549
were selected not only because the lung is a primary site
of nanoparticles retention after inspiration21, but also
because A549 cells represent a preference model to study
toxicity mediated by ROS generation27–29. The brain
microglial cells BV-2 were chosen since they represent a
valid model system alternative to primary microglia cul-
tures30, with which they share as a common feature the
responses to inflammatory stimuli and trophic factors31.
Additionally, in order to understand the impact of ECNs
on different cellular biochemical functions, we used
selected non-cytotoxic ECNs concentration to determine
its influence on nitric oxide (NO) and total ROS pro-
duction, and of metabolites related to energy metabolism,
mitochondrial functions, oxido-reductive reactions, and
antioxidant defences.
Results
Effect of ECNs and DPPC:POPG(7:3)/ECNs on A549 and BV-
2 cells toxicity
The first aim of the present study was to investigate the
toxicity of different concentrations of ECNs on A549 and
BV-2 cells. This was done both in the absence and pre-
sence of lipids (DPPC:POPG(7:3)) that were used as
model LS (biological) systems that are expected to coat
ECNs that enter the body through the respiratory route. A
representative picture at low (2 h after seeding) and high
density for both A549 and BV-2 cells employed in our
study is shown in Supplementary Figure 1. Incubation of
A549 or BV-2 cells for 24 h with increasing concentration
(2, 5, 10, 50, or 100 µg/mL) of ECNs provoked a dose-
dependent increase in cell toxicity (Fig. 1A, B). Maximal
decrease in cell viability was obtained when using 100 µg/
mL ECNs (−53 and −65% in A549 or BV-2 cells,
respectively, p< 0.01 compared to resting (untreated)
cells). The presence of DPPC:POPG(7:3) in combination
with ECNs produced significant protection only when
both cell types were treated with high doses (50 and 100
µg/mL) of ECNs.
From this set of data, we were able to select the nano-
particle concentration (2 µg/mL) that produced a decrease
in cell viability, in both A549 or BV-2 cells, lower than 5%.
Additionally, we also excluded from further experiments
the use of artificial LS since, at this selected ECNs con-
centration, no differences were recorded in cell viability in
presence or absence of DPPC:POPG(7:3).
To further confirm the results on cell viability obtained
with the MTT assay, we performed additional experi-
ments measuring release of lactate dehydrogenase in the
culture media, as an index of cell necrosis. Moreover, we
also evaluated cell proliferation and survival using the
XTT assay and the trypan blue test, respectively. Com-
pared to resting cells, the treatment with 2 µg/mL ECNs
for 24 h provoked an increase in LDH release in A549
(+4%) and BV-2 (+5%) cells (Supplementary Figure 2)
that was similar in magnitude to the results of the MTT
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test (see Fig. 1). Additionally, values of cell proliferation
and survival were very similar between resting and ECNs-
treated cells (Supplementary Tables 1 and 2).
Supplementary Figure 3 shows the effect of longer times
of cell exposition (48 and 72 h) to 2 µg/mL ECNs. As in
the case of 24 h incubation, the decrease in viability
observed in A549 and BV-2 cells was quite low for both
incubation times compared to resting cells, with a resting/
ECNs-treated cells ratio equal to 1.13 and 1.16 for A549
and BV-2 cells, respectively, after 72 h.
Effect of ECNs on NO production of cultured lung and
microglial cells
Figure 2 shows the effect of apparently non-cytotoxic
ECN concentrations on the intracellular and extracellular
NO production (as determined by Griess assay) in cul-
tured A549 (Panel A) and BV-2 (Panel B) cells. The
addition of ECNs to the culture medium of A549 for 24 h
did not significantly affect the extracellular NO con-
centration but provoked a 68% increase in the intracel-
lular NO concentration (p< 0.001 compared to control
cells). Differently, microglial BV-2 cells underwent dra-
matic increase in both extracellular and intracellular NO
generation. Particularly, 210 and 121% increase, respec-
tively, in extracellular and intracellular NO production (p
< 0.001 respect to control resting cells) was measured
after 24 h incubation with a dosage of ECNs (2 μg/mL)
that did not cause significant decrease in cell viability. The
1 h pre-treatment of A549 or BV-2 cells with L-NAME
(500 µM) or L-MMA (1mM), two well-known iNOS
inhibitors, almost completely abolished the difference in
NO production between resting and ECNs-treated cells
(Supplementary Figure 4).
ROS production induced by non-toxic ECNs concentration
in cultured lung and microglial cells
Results illustrated in Fig. 3 demonstrate that a non-toxic
ECNs concentration is capable to cause a 57 and 83%
increase in total ROS production (as determined by ME-
LIF) in cultured A549 (Panel A) and BV-2 (Panel B) cells,
respectively (p< 0.001 compared to resting cells). To
counteract ECNs-mediated ROS overproduction, we tes-
ted the effect of 10 mM N-acetyl-L-histidine or carnosine
by pre-treating both cell lines for 1 h before their chal-
lenge with ECNs at 2 μg/mL. Either in lung or microglial
cells, N-acetyl-L-histidine was more effective than car-
nosine in decreasing ECNs-induced ROS generation. In
fact, respect to control resting cells, a still 20% higher ROS
formation was measured in ECNs-carnosine treated cells
(p< 0.01 respect to both resting and ECNs-treated cells),
whilst ECNs-N-acetyl-L-histidine treated cells had levels
of ROS not significantly different from those measured in
resting cells (p< 0.001 compared to ECNs-treated cells).
To investigate the observed effect on ROS production
by cultured A549 and BV-2 cells in the presence of N-
acetyl-L-histidine or carnosine, we performed additional
experiments in which ROS production was measured
after incubating the cells for 24 h with ECNs following a 1
h pre-incubation with β-alanine, L-histidine, or β-alanine
+ L-histidine (all at 10 mM). In stimulated A549 and BV-
2 cells, neither β-alanine nor L-histidine nor their equi-
molar combination induced a significant decrease in ROS
production if compared to the treatment with carnosine
or N-acetyl-L-histidine (data not shown).
Influence of non-toxic ECNs concentration on energy
metabolism, mitochondrial functions, nicotinic coenzymes,
and oxidant/antioxidant balance of cultured lung and
microglial cells
Table 1 summarizes results of the effect of the addition
to the culture medium for 24 h of non-toxic ECNs
Fig. 1 Change in the cell viability caused by challenging for 24 h
A549 (Panel A) and BV-2 (Panel B) cells with increasing
concentration (2, 5, 10, 50, or 100 µg/mL) of ECNs or DPPC:POPG
(7:3)/ECNs. Data are the mean of four independent experiments and
are expressed as the percent variation with respect to the viability
recorded in control cultures. Standard deviations are represented by
vertical bars. *Significantly different from resting (control) cells, p <
0.01; **Significantly different from corresponding concentration of
ECNs in absence of DPPC:POPG(7:3), p < 0.01
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amount, on parameters related to energy metabolism and
mitochondrial functions of cultured A549 and BV-2 cells.
In both cell lines, the energy state, evaluated in terms of
concentrations of ATP, ADP, AMP, and energy charge
potential (ECP=ATP+ 1/2 ADP/ATP+ADP+AMP)
was negatively affected by 2 μg/mL ECNs. Significant −23
and −29% decrease of ATP in A549 and BV-2 cells,
respectively, (p< 0.001 compared to resting cells) was
accompanied by modest increase in ADP and an
impressive increase in AMP (+338 and +418%, respec-
tively, in A549 and BV-2 cells; p< 0.001 compared to
resting cells). The imbalance in adenine nucleotide
homeostasis in both cell lines, consequently caused sig-
nificant decrease in ECP (p< 0.001 compared to resting
cells), which is a good measure of the cell energy state.
Using the values of the concentrations of ATP and ADP
(expressed as nmol/mg protein), it was possible to cal-
culate the ATP/ADP ratio, which is considered as a reli-
able index of the mitochondrial phosphorylating
capacity32. A549 and BV-2 cells showed decrease in the
ATP/ADP ratio by −32 and −58%, respectively, (p<
0.001 compared to resting cells) indicating either that
Fig. 2 Intracellular and extracellular concentrations of NO (as determined by Griess assay) in resting and ECNs-stimulated (24 h) A549
(Panel A) and BV-2 (Panel B) cells. Data are the mean of four independent experiments. Standard deviations are represented by vertical bars.
*Significantly different from resting (control) cells, p < 0.001
Fig. 3 Total ROS production (as detected by microchip electrophoresis with laser-induced fluorescence) in resting and ECNs-stimulated
(24 h) A549 (Panel A) and BV-2 (Panel B) cells. Carnosine and N-acetyl-L-histidine (N-Ac-Histidine) (10 mM) are pre-treatments (1 h). Data are the
mean of 4 independent experiments and are expressed as the percent variation with respect to the total ROS production recorded in control
cultures. Standard deviations are represented by vertical bars. *Significantly different from resting (control) cells, p < 0.001; **Significantly different
from resting (control) cells, p < 0.01; ***Significantly different from ECNs-treated cells, p < 0.01; ****Significantly different from ECNs-treated cells, p <
0.001
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non-toxic levels of ECNs deeply alter the main mito-
chondrial function, i.e., to ensure adequate energy supply
to the cell, or that microglial cells are more sensitive to
the negative effects induced on cell metabolism by ECNs.
Results reported in Table 2 strongly demonstrate that
the ECNs concentration non-toxic for cell viability (2 μg/
mL) was however capable to deeply affect concentrations
of purine (GTP, GDP, GMP, IMP) and pyrimidine (UTP,
UDP, UMP, CTP, CDP, CMP) nucleotides, causing an
overall dramatic depletion of the cellular stores of high
energy phosphates (each of these compounds was sig-
nificantly different from resting cells in both A549 and
BV-2, p< 0.01).
Data referring to oxidized (NAD+ and NADP+) and
reduced (NADH and NADPH) nicotinic coenzymes in
resting A549 and BV-2, and in cells challenged with
a non-toxic ECNs concentration are summarized in
Table 3. ECNs at 2 μg/mL produced a significant decrease
in NAD+ and NADP+ concentrations in both cell lines (p
< 0.01 compared to resting cells), with concomitant
increase in NADH and decrease in NADPH. In con-
sequence of these changes, either the NAD+/NADH or
the NADP+/NADPH ratio were modified by ECNs. A
−44 and −30% decrease of NAD+/NADH and NADP+/
NADPH ratio, respectively, was observed in A549 treated
cells (p< 0.001 in comparison with resting cells), while
−35 and −13% of these values were found in BV-2 treated
cells (p< 0.001 compared to resting cells). It should also
be considered that the total pool of nicotinic coenzymes
(NAD++NADH+NADP++NADPH) was 22.56 nmol/
mg protein in resting A549 and 39.07 nmol/mg protein in
resting BV-2. In ECNs-stimulated A549 and BV-2 cells,
these values were 17.61 (−22%, p< 0.001 compared to
resting cells) and 31.09 nmol/mg protein (−20%, p<
0.001 compared to resting cells), respectively, indicating
an equal depletion of the total nicotinic coenzyme pool
induced by the non-cytotoxic ECNs treatment.
In Table 4, the values of reduced glutathione (GSH), the
water-soluble low-molecular weight antioxidant
protecting free-SH groups of proteins, of mal-
ondialdehyde (MDA), an end-product of ROS mediated
peroxidation of fatty acids of membrane phospholipids,
and of nitrite and nitrate, the end-products of NO
metabolism, are summarized. Significant decrease by 59
and 61% respect to resting cells (p< 0.001) of GSH was
recorded in ECNs-treated A549 and BV-2, respectively.
Concomitantly, three times higher MDA values were
measured in both stimulated cell lines (p< 0.001 com-
pared to resting cells) being suggestive of significant ROS
mediated damages to biological membranes. Intracellular
nitrite and nitrate (measured by HPLC using a method for
their direct detection, with no derivatization) were sta-
tistically higher in ECNs treated cells (p< 0.001 compared
to resting cells). The nitrite+ nitrate sum was 6.61 and
12.63 nmol/mg protein in resting A549 and BV-2 cells,
respectively. Values of this sum in cells treated with non-
toxic ECNs were 10.83 (+64%) and 23.22 (+84%) nmol/
mg protein (p< 0.001 compared to resting cells), indir-
ectly indicating a remarkable increase in NO production
during the 24 h challenge with ECNs.
Discussion
The use of nanoparticles in industry, biology, and
medicine is attracting increasing attention. In particular
carbon nanoparticles have been recently considered as
new emerging tools for delivery systems for cancer ther-
apy and have contributed to therapeutic strategies against
different neurological disorders33 including Alzheimer's
disease34, 35. Therefore, several studies have been aimed in
evaluating their biosafety, toxicity, and/or possible side
effects both in vitro and in vivo36. These information are
of paramount importance to finalize the use of nano-
particles for therapeutic applications (e.g., drug delivery).
Notwithstanding, their effects on cell metabolism have
not yet been fairly described. Particularly, no results have
been to date produced on the influence of non-cytotoxic
concentrations of ECNs on cell metabolism and mito-
chondrial functions.
Table 1 Effect of 24 h of incubation of alveolar basal epithelial A549 and microglial BV-2 cells with engineered carbon
nanodiamonds (ECNs) on adenine nucleotides (mono, di, and triphosphorylated), cell energy state (ECP) and
mitochondrial phosphorylating capacity (ATP/ADP ratio)
ATP (nmol/mg protein) ADP (nmol/mg protein) AMP (nmol/mg protein) ECP ATP/ADP
Resting A549 95.07 (19.02) 8.25 (2.03) 1.24 (0.34) 0.96 (0.11) 11.52 (1.12)
A549 + ECNs 72.73* (14.58) 9.34** (1.18) 4.19* (0.72) 0.89* (0.12) 7.79* (0.65)
Resting BV-2 123.90 (29.68) 15.93 (2.35) 2.07 (0.62) 0.93 (0.07) 7.78 (1.12)
BV-2 + ECNs 87.87* (17.42) 26.83* (5.65) 8.66* (1.51) 0.82* (0.11) 3.28* (0.94)
Values are the mean of four different experiments. Standard deviations are in parenthesis. Incubation conditions and HPLC method to separate simultaneously the
indicated compounds are given in Materials and methods
ECNs engineered carbon nanodiamonds, ATP, ADP, AMP adenosine mono, di, triphosphate, respectively; ECP energy charge potential (ATP + 1/2 ADP/ATP + ADP +
AMP)
*Significantly different from resting, p < 0.001; **Significantly different from resting, p < 0.05
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The experiments described in the present study were
purposely designed in order to determine, in two different
alveolar basal epithelial A549 and brain microglial BV-2
cell lines, whether non-cytotoxic amount of ECN was
capable to cause increase in NO and ROS production and
to induce significant modifications in mitochondrial
functions and energy metabolism. Results indicate that: (i)
ECNs caused a dose-dependent decrease in cell viability of
A549 or BV-2 cells, with maximal decrease obtained when
using 100 µg/mL ECNs; (ii) the presence of lipid mixtures
(DPPC:POPG(7:3)) mimicking the composition of LS
provided additional protections against ECNs toxicity
only at very high ECN concentrations (50 and 100 µg/
mL); (iii) non-cytotoxic ECN concentrations were able to
increase both total NO (intracellular+ extracellular) and
ROS production in both cell lines; (iv) nanoparticle
treatment of A549 and BV-2 cells negatively affected
concentrations of high-energy phosphates, nicotinic
coenzymes, and GSH, indicating imbalance of energy
metabolism and mitochondrial functions and sustained
oxidative/nitrosative stress (increase in MDA and NO
metabolites).
According to the results on ECNs toxicity, we found no
differences in the survival of the two alveolar basal epi-
thelial (A549) or brain microglial (BV-2) cell lines. This
finding is of relevance since it has been shown that ECNs
administered in vivo are capable to cross the blood brain
barrier (BBB)37. Therefore, it is conceivable that repeated
administration of ECNs, particularly under conditions of
transitory or permanent BBB breakdown, such as in brain
ischemia38, in traumatic brain injury39 or in various
chronic neurodegenerative disorders40, may produce
accumulation in the brain tissue at levels capable to cause
cell death. In this context, we found that the surrogate of
LS DPPC:POPG(7:3) was scarcely effective in increasing
survival of alveolar basal epithelial and microglial cells
treated with ECNs, unless challenge with nanoparticles
was carried out at high ECN concentrations (Fig. 1).
On the basis of the change in cell survival to increasing
ECN concentrations, we were interested in determining
the effects of the maximal non-cyctotoxic dose of ECNs
on various aspects of cell functions, including oxidative/
nitrosative stress, energy metabolism, and mitochondrial
phosphorylating capacity. Our results indicate that this
ECN concentration (2 µg/mL) stimulates overproduction
of NO (Fig. 2) and ROS (Fig. 3) in both cell lines. As
expected, BV-2 cells (brain macrophages) showed higher
NO production than A549 cells (alveolar basal epithelial
cells). In both cell lines, results with nitric oxide synthase
inhibitors (Supplementary Figure 4) clearly showed that
NO production mostly occurred through iNOS activation.
Both NO and ROS production were effectively counter-
acted by the treatment with the antioxidants N-acetyl-L-
histidine and carnosine (Fig. 3). This finding is inTa
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accordance with previous data showing induction of ROS
generation, increased cytoplasmic Ca2+ content, produc-
tion of TNF-α, and enhanced caspase-3 activity, when
using cationic nanoparticles (Si and Ge nanoparticles) for
the treatment of rat alveolar macrophage (NR8383) and
human colonic adenocarcinoma (Caco-2) cells41. Addi-
tionally, Pattani et al. reported the in vitro and in vivo
effects of chitosan nanoparticles on NO production, IL-6
gene expression, and lymphocyte proliferation42. A dose-
dependent increase in NO production was observed in
peripheral blood mononuclear cells accompanied by
lymphocyte proliferation. In the same study, the increase
in NO production was also showed in vivo in a wound
healing model. On the other hand, divergent results
indicating that cerium oxide (CeO2) and yttrium oxide
(Y2O3) nanoparticles decrease oxidative stress-induced
apoptosis in isolated rat pancreatic islets exposed to
hydrogen peroxide were proved by Hosseini et al.43. It is
worthwhile recalling that our results, demonstrating sus-
tained oxidative/nitrosative stress caused by challenge of
alveolar basal epithelial and brain microglia cells with
non-cytotoxic ECN levels, were obtained either by directly
measuring NO and ROS formation using advanced
microfluidic techniques, or by measuring stable end-
products of NO metabolism (nitrite and nitrate) and of
ROS-mediated lipid peroxidation (MDA) using well
established HPLC methods. Furthermore, these data were
strongly corroborated by the significant GSH depletion
determined in same cell extracts (Table 4).
The experimental design we used in this study allowed
to evidence that non-cytotoxic ECN dose was however
capable to produce negative effects on fundamental
metabolic functions connected to energy metabolism and
mitochondrial functions. In particular, we observed an
ATP decline by 23.5 and 29.1% in alveolar basal epithelial
and brain microglial cells, respectively, that was accom-
panied by increase in ADP and AMP with consequent
decrease in the value of the ECP. This indicates a state of
energy penalty caused by imbalance in the main mito-
chondrial function that is to provide adequate ATP supply
to ensure all the energy consuming reactions within cells.
Malfunctioning of mitochondria was clearly evidenced by
the decrease in the ATP/ADP ratio (Table 1), which is
considered a good indicator of the mitochondrial phos-
phorylating capacity32, 44. The imbalance in energy
metabolism caused by mitochondrial malfunctioning
Table 3 Effect of 24 h of incubation of alveolar basal epithelial A549 and microglial BV-2 cells with engineered carbon
nanodiamonds (ECNs) on oxidized and reduced nicotinic coenzymes
NAD+ (nmol/mg
protein)
NADH (nmol/mg
protein)
NADP+ (nmol/mg
protein)
NADPH (nmol/mg
protein)
NAD+/NADH NAPD+/NAPDH
Resting A549 16.92 (4.28) 1.25 (0.48) 3.96 (0.94) 0.43 (0.05) 13.54 (1.87) 9.21 (1.29)
A549 + ECNs 13.77* (2.59) 1.83* (0.56) 1.74* (0.62) 0.27* (0.07) 7.52* (1.05) 6.44* (0.65)
Resting BV-2 29.88 (2.32) 2.95 (0.30) 5.53 (0.82) 0.71 (0.06) 10.13 (1.55) 7.79 (0.84)
BV-2 + ECNs 23.04* (5.24) 3.52* (0.61) 3.95* (0.91) 0.58* (0.04) 6.54* (0.94) 6.81* (0.72)
Values are the mean of four different experiments. Standard deviations are in parenthesis. Incubation conditions and HPLC method to separate simultaneously the
indicated compounds are given in Materials and methods
ECNs engineered carbon nanodiamonds, NAD+ oxidized nicotinamide adenindinucleotide, NADH reduced nicotinamideadenindinucleotide, NADP+ oxidized
nicotinamideadenindinucleotide phosphate, NADH reduced nicotinamideadenindinucleotide phosphate
*Significantly different from resting, p < 0.001
Table 4 Effect of 24 h of incubation of alveolar basal epithelial A549 and microglial BV-2 cells with engineered carbon
nanodiamonds (ECNs) on GSH and parameters related to oxidative (MDA) and nitrosative stress (nitrite, nitrate)
GSH (nmol/mg protein) MDA (nmol/mg protein) Nitrite (nmol/mg protein) Nitrate (nmol/mg protein)
Resting A549 0.49 (0.09) 0.008 (0.002) 0.04 (0.01) 6.57 (0.85)
A549 + ECNs 0.20* (0.04) 0.025* (0.008) 0.17* (0.05) 10.66* (1.89)
Resting BV-2 0.38 (0.06) 0.010 (0.003) 0.11 (0.03) 12.52 (5.77)
BV-2 + ECNs 0.15* (0.05) 0.031* (0.007) 0.31* (0.07) 22.91* (7.06)
Values are the mean of four different experiments. Standard deviations are in parenthesis. Incubation conditions and HPLC method to separate simultaneously the
indicated compounds are given in Materials and methods
ECNs engineered carbon nanodiamonds, GSH reduced glutathione, MDA malondialdehyde
*Significantly different from resting, p < 0.001.
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observed in our experiments was strongly reinforced by
data referring to the decrease in triphophate nucleotides
GTP, UTP, and CTP, accompanied by the increase in
their corresponding di- and monophosphate forms
(Table 2), indicating a generalized depletion of high
energy compounds leading to significant cell energy crisis.
Under these conditions of energy penalty and mitochon-
drial malfunctioning, it has been demonstrated that the
complex mechanisms of the mitochondrial quality con-
trol, involving a complex system of genes and proteins
that regulate the life of these organelles45, 46, are shifted
towards fission and mitophagy47, 48, two processes that
irreversibly compromise cell metabolism.
These findings are in line with results reported by Cui
et al. who demonstrated in E. coli the ability of gold
nanoparticles to collapse the mitochondrial membrane
potential, to inhibit ATP synthase activities decreasing the
ATP level, and to inhibit the binding of ribosome subunit
to tRNA indicating a collapse of biological process49. Cell
energy dysmetabolism along with the production of pro-
inflammatory cytokines and cytotoxicity were also
observed when using surface-functionalized silicon and
germanium nanoparticles41. However, opposite results
were reported by Suh et al. who showed that gold nano-
particles are able to prevent antimycin-A induced mito-
chondrial membrane potential dissipation, complex IV
inactivation, ATP loss, Cyt c release, cardiolipin perox-
idation, and oxidant generation in MC3T3-E1 osteoblastic
cells50.
Treatment with non-cytotoxic dose of ECNs also pro-
duced depletion of the nicotinic coenzyme pool (NAD+,
NADH, NADP+, and NADPH) (Table 3), therefore
decreasing the correct supply of reducing equivalents for
the mitochondrial electron transfer chain, as well as
compromising the efficiency of all the oxido-reductive
reactions in which these coenzymes are involved. This
phenomenon has been observed in various experimental
conditions characterized by energy penalty, such as
myocardial ischemia and reperfusion51 and traumatic
brain injury52, 53. Results related to nicotinic coenzymes
also indicate that non-cytotoxic ECNs dose produced a
significant decrease in the NAD+/NADH ratio. From a
biochemical point of view, this is equivalent to a decrease
in the lactate/pyruvate ratio and indicates an increased
rate of glycolysis. Compensatory higher glycolytic rate
occurs either because of decreased oxygen availability or,
if oxygen is maintained constant as in our experiments,
because of impaired mitochondrial functions with the aim
of limiting decrease in ATP supply.
According to the results of the present study it is now
possible to affirm that ECNs, even when used at non-
cytotoxic dose, may produce relevant biochemical
alterations involving not only sustained oxidative/
nitrosative stress, but also profound imbalance in energy
metabolism and mitochondrial functions. Since ECNs
(and carbon-based nanomaterials in general) might find
biomedical applicability either as drug carriers54 or as
antineoplastic agents55, these new information are of
significant utility for both possibilities. In the first pos-
sible application, it should be taken in great account the
negative activities on different cell functions of ECNs as
potential damaging side-effects that might limit their
use even at low dosage. In the latter possible application,
the imbalance of cell metabolism might be crucial if
ECNs were selectively directed toward cancer cells and
used as disruptors of energy homeostasis and mito-
chondrial functions of the target cells. In this context,
Das et al. demonstrated that PLGA-loaded-nano-
apigenin are very potent inhibitors of skin tumorigen-
esis through various mechanisms including mitochon-
drial dysfunction, ROS production, antioxidant
depletion, and apoptosis55.
Conclusion
Even though further studies are needed to evaluate the
molecular mechanisms behind the biochemical alterations
observed upon nanoparticles addition to the cell cultures,
our findings highlight the importance of investigating the
modulation of energy metabolism as well as NO and ROS
production at cellular level even at very low-dose,
apparently non-toxic, nanoparticle concentrations. The
present study indicates that a much better comprehension
of the molecular and biochemical changes caused by the
interaction of ECNs (and nanoparticles in general) with
living cells is mandatory before these highly promising
tools might find the correct application in the biomedical
field.
Materials and methods
Materials and reagents
Alveolar basal epithelial A549 cells (ATCC® CCL-
185™), RPMI-1640 medium, trypsin-EDTA solution, fetal
bovine serum, and penicillin/streptomycin antibiotic
solution were purchased from American Type Culture
Collection (ATCC, Manassas, VA, USA). Microglial BV-2
cells (ICLC ATL03001) were purchased from Interlab Cell
Line Collection (ICLC, Genova, Italy). Ultrapure stan-
dards for HPLC, tetrabutylammonium hydroxide, MTT
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide] tetrazolium salt, In Vitro Toxicology Assay Kit,
lactic dehydrogenase based, Cell Proliferation Kit II
(XTT), L-NG-nitroarginine methyl ester (L-NAME), NG-
monomethyl-L-arginine (L-MMA), L-histidine, β-alanine,
L-carnosine, Griess reagent (modified), anhydrous dime-
thyl sulfoxide, potassium chloride, sodium dodecyl sulfate
(SDS), phosphate-buffered saline (PBS), trypan blue
solution, and sodium nitrite were all supplied by Sigma-
Aldrich (St. Louis, MO, USA). HPLC-grade methanol, far-
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UV acetonitrile, and HPLC-grade chloroform were sup-
plied by J. T. Baker Inc. (Phillipsburgh, NJ, USA). 2′,7′-
dichlorodihydrofluorescein diacetate (H2DCFDA), phenol
red-free RPMI-1640, N-acetyl-L-histidine, boric acid,
sodium hydroxide, acetone, 2-propanol, and ethanol
(95%) were obtained from Thermo Fisher Scientific Inc.
(Pittsburgh, PA, USA). Polyethersulfone membrane (3 K)
was purchased from VWR International (West Chester,
PA, USA). C-Chip disposable hemocytometer was pur-
chased from Bulldog Bio, Inc. (Portsmouth, NH, USA).
Sylgard 184 polydimethylsiloxane (PDMS) prepolymer
and curing agent were obtained from Ellsworth Adhesives
(Germantown, WI, USA). Organic (chloroform) mixtures
of the phospholipids, dipalmitoyl phosphatidylcholine
(DPPC, 25mg/ml) and 1-palmitoyl-2-oleoyl-sn-glyc-ero-
3-phospho-(1′-rac-glycerol) (POPG, 10mg/ml) used for
this study were obtained from Avanti Polar Lipids Inc.
(Alabaster, AL, USA). ECNs used in this research were
obtained from Microdiamant (Lengwil, Switzerland).
Nitrogen tanks for drying were supplied by Matheson Tri-
Gas Inc. (Basking Ridge, NJ, USA). All water used was
Ultrapure (18.3MΩ cm) (Milli-Q Synthesis A10, Milli-
pore, Burlington, MA, USA).
Preparation of nanoparticle suspensions
Sample solutions of DPPC:POPG in 7:3 molar ratio
were prepared in HPLC grade chloroform. This particular
molar ratio was selected as a model mixture to emulate
other synthetic LS compositions. The lipid mixtures were
then dried with nitrogen and kept under vacuum over-
night. The completely dried lipids were then suspended in
PBS (pH 7.4) at a concentration of 10 mg/ml in a Preci-
sion water bath system (Thermo Fisher Scientific Inc.,
Pittsburgh, PA, USA) at 45 °C. This temperature was
selected because the phase transition temperature of
DPPC is 41 °C. ECN suspensions, prepared in PBS (pH
7.4), were sonicated for 2 h. Sonication is an essential step
to prevent aggregation of the nanoparticle mixture. ECNs
(1 wt. %) were then added to the phospholipid mixture for
further studies.
Nanoparticle characterization
Size distribution of ECNs, in water, was obtained
using Dynamic Light Scattering (NanoBrook Omni,
Brookhaven instruments Corporation, Holtsville, NY,
USA) after 2 h of sonication. In water, the effective size
was 219 nm with a polydispersity of 0.19. We monitored
particle size for another half hour, which showed no
change. A zeta potential of −28 mV was obtained in
potassium chloride solution using the same instrument.
TEM images of the ECNs originally suspended in water
and organic solvent and AFM images of ECNs in the
absence and presence of LS were previously reported by
Chakraborty et al.16.
Cell culture and treatment protocol
Alveolar basal epithelial A549 cells and microglial BV-2
cells were cultured in RPMI-1640 containing 10% (v/v)
fetal bovine serum, streptomycin (0.3 mgmL–1), and
penicillin (50 IUmL–1). The cells were cultured in 75 cm2
polystyrene culture flasks at a density of 5× 106 cells/
flask, maintained in a humidified environment at 37 °C
and 5% CO2, and passaged every 3–5 days, before they
become confluent, to avoid overgrowth.
On the day of the experiment cells were harvested,
counted, and plated at a density of 5× 106 cells/flask. Cells
plated in 48-well plates (15× 104 cells/well) as well as the
treatment with ECNs in presence of LS (DPPC:POPG(7:3)/
ECNs) were used only for the determination of cell viability
using the MTT assay. After 2 h cells were treated with
nanoparticles (ECNs or DPPC:POPG(7:3)/ECNs) and
incubated for 24 h in a humidified environment (37 °C and
5% CO2). For experiments carried out to investigate the
antioxidants activity, cells were pre-treated with N-acetyl-
L-histidine or carnosine (both of them at 10mM final
concentration) for 1 h prior to the treatment with nano-
particles. Resting cells were always used as control. At the
end of 24 h incubation, to analyze intracellular ROS pro-
duction, the cells were washed twice using 5mL of cold 10
mM PBS at pH 7.4 and then incubated with phenol red-
free RPMI-1640 containing H2DCFDA dye. Fresh stock
dye solution of 10mM H2DCFDA was prepared in 99%
sterile dimethyl sulfoxide prior to each experiment. Next,
10 µL of this solution was added to each culture flask (10
μM H2DCFDA final concentration) and allowed to react
for 60min in a humidified environment (37 °C, 5% CO2).
Cells were then washed using 5mL of cold 10mM PBS at
pH 7.4 and harvested using 2.5mL of trypsin-EDTA
solution (0.25% Trypsin/0.53mM EDTA in Hanks
Balanced Salt Solution without calcium or magnesium).
One hundred µL of the cell suspension was removed for
cell counting before centrifuging the suspension at 125×g
for 5min at 4 °C. The supernatant was removed and the
cell pellet was washed twice using cold 10mM PBS at pH
7.4. Cells were lysed using 50 µL of pure ethanol and fil-
tered by centrifugation at 18.690×g for 10min at 4 °C in
centrifuge tubes equipped with 3 kDa molecular weight
cut-off filters. Ten microliter of this solution was added to
90 µL of running buffer consisting of 10mM boric acid and
7.5mM SDS at pH 9.2 (10% ethanol final concentration)
and then analyzed with the microfluidic device56, while the
stable nitric oxide end-product nitrite was measured using
the Griess assay57.
The number of live cells was determined using the
trypan blue exclusion assay. The cell suspension was
diluted 1:1 to 1:3 (based on cell density) with 0.4%
trypan blue solution. The cell density for each sample
was determined using a C-Chip disposable
hemocytometer.
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Total ROS detection using microchip electrophoresis with
laser-induced fluorescence (ME-LIF)
The fabrication of hybrid polydimethylsiloxane-glass
microfluidic devices to carry out the ME-LIF experiments
has been described previously56, 58. Briefly, SU-8 10
negative photoresist was spin-coated onto a 4-inch dia-
meter silicon wafer with a resulting thickness of 15± 1
mm employing a Cee 100 spin coater (Brewer Science
Inc., Rolla, MO, USA). The obtained wafer was soft baked
in two steps (pre-baked at 65 °C for 2 min and ramping to
soft bake temperature of 95 °C for additional 5 min) using
a hotplate (Thermo Scientific, Asheville, NC, USA). The
selected software employed for microfluidic channel
designs was AutoCad LT 2004 (Autodesk Inc., San Rafael,
CA, USA). The designed geometry was printed onto a
transparency film at a resolution of 50000 dpi (Infinite
Graphics Inc., Minneapolis MN, USA). A transparency
film mask was used to cover the coated wafer that was
subsequently exposed (344 mJ cm2; 16 s) to UV light (i-
line) (ABM Inc., San Jose, CA, USA). The wafer after UV
exposure was post-baked in two steps (65 °C for 2 min and
95 °C for 10min) and then developed in SU-8 developer,
rinsed using 2-propanol (IPA), and dried with nitrogen. A
“hard-bake” was performed at 180-200 °C for 2 h. A pro-
filometer (Alpha Step-200, Tencor Instruments, Moun-
tain View, CA, USA) was employed to confirm the
thickness of the raised photoresist, which corresponds to
the depth of the polydimethylsiloxane (PDMS) channels.
PDMS microchips were made by pouring PDMS pre-
polymer and curing agent (1:10 ratio) on the surface of the
master that was subsequently placed in an oven at 70 °C
overnight. We performed our experiments using a simple-
T device with a 5 cm separation channel and 0.75 cm side
arms (Fig. 4). A 4mm biopsy punch (Harris Uni-core, Ted
Pella Inc., Redding, CA, USA) was used to create the holes
for all reservoirs (sample, buffer, ground). In order to
complete the final hybrid PDMS-glass microchip device,
the PDMS layer containing the embedded channels
(presenting a width and a depth of 50 mm and 14mm,
respectively) was sealed to a borofloat glass plate.
Prior to analyzing each cell lysate, the PDMS-glass
device was flushed with 0.1M NaOH for 5 min, followed
Fig. 4 A schematic illustration of chip geometry (simple-T 5 cm microchip design) with applied voltages and ME-LIF setup. GND ground, PMT
photomultiplier tubes
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by a 5-min flush with running buffer (10 mM boric acid,
7.5 mM SDS at pH 9.2). Separations were performed in
the normal polarity mode using a 30 kV high voltage
power supply (Ultravolt, Ronkonkoma, NY, USA). For all
separations, +2400 V was applied to the running buffer
reservoir while +2200 V was applied to the sampling
reservoir. The sample was introduced into the separation
channel using a 1-s gated injection59. In order to remove
any residual sample, the system was flushed for 60 s with
running buffer after the analysis of each sample.
Excitation, detection, data acquisition, and data analysis
were carried out using the same technologies and pro-
grams already described elsewhere57. A schematic illus-
tration of chip geometry and ME-LIF setup is shown in
Fig. 4.
Indirect NO determination using the Griess assay
The stable NO end-product nitrite was measured using
the Griess assay as previously described by Caruso et al57.
MTT assay
The toxicity of the different preparation of nanoparticles
(ECNs or DPPC:POPG(7:3)/ECNs) was measured through
the determination of cell viability using the MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]
assay as previously reported60.
HPLC analysis of metabolites
Both A549 and BV-2 cells were deproteinized after 24 h
of incubation without and with non-toxic amount of
nanoparticles. At the end of the incubation, cells were
pelleted and washed twice with large volumes of cold 10
mM PBS at pH 7.4. After the second washing, cells were
deproteinized according to the organic solvent deprotei-
nization, suitable to measure acid labile and easily oxi-
dizable compounds described in detail elsewhere61.
The simultaneous separation of high-energy phosphates
(ATP, ADP, AMP, GTP, GDP, GMP, IMP, UTP, UDP,
UMP, CTP, CDP, CMP), nicotinic coenzymes (NAD+,
NADH, NADP+, NADPH), reduced glutathione (GSH),
MDA, nitrite and nitrate in the protein-free cell extracts
(200 μL) was carried out using previously established ion
pairing HPLC methods61, 62, which utilize tetra-
butylammonium hydroxide as the pairing reagent. Separa-
tion was obtained using a Hypersil C-18, 250× 4.6mm, 5
µm particle size column, provided with its own guard col-
umn (Thermo Fisher Scientific, Rodano, Milan, Italy). The
HPLC apparatus consisted of a SpectraSYSTEM P4000
pump system (Thermo Fisher Scientific) and a highly-
sensitive UV6000LP diode array detector (Thermo Fisher
Scientific), equipped with 5 cm light path flow cell and set
up between 200 and 300 nm wavelength. Assignment and
calculations of the compounds of interest in chromato-
graphic runs of cell extracts were performed by comparing
retention times, absorption spectra, and area of the peaks
(calculated at 260 nm wavelength in the case of high energy
phosphates and nicotinic coenzymes, at 266 nm wavelength
for MDA, or at 206 nm wavelength for GSH, nitrite and
nitrate) of chromatographic runs of mixtures containing
known concentrations of true ultrapure standard mixtures.
Cell imaging
Images of A549 and BV-2 cells were obtained using an
Accu-Scope microscope (Mel Sobel Microscopes Ltd,
Hicksville, NY, USA) equipped with MicroPublisher 3.3
RTV camera (Qimaging, Surrey, BC, Canada). QCapture
Pro 6 (Qimaging) was the selected software used for the
image analysis.
Statistical analysis
Normal data distribution in this work was determined
using the Kolmogorov-Smirnov test. The within-group
comparison was performed by one-way analysis of var-
iance (ANOVA) while differences across groups were
determined by two-way ANOVA. Fisher’s Protected Least
Squares Differences was used as the post hoc test. Only
two-tailed p-values less than 0.05 were considered sta-
tistically significant.
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